摘要
目的:观察米非司酮与孕三烯酮应用于盆腔子宫内膜异位症术后患者巩固治疗的疗效。方法:选择2008年6月～2009年6月在江山市中医院进行保守性手术治疗并经病理证实为盆腔子宫内膜异位症患者68例,随机分为两组:米非司酮组34例,给予米非司酮口服,12.5 mg/天;孕三烯酮组34例,给予孕三烯酮口服2.5 mg,每周2次。两组均于术后1周开始用药,疗程6个月;定期随访。结果:米非司酮及孕三烯酮组患者持续治疗半年,与治疗前比较,各组子宫内膜异位症引起的痛经等各种疼痛症状得到明显改善(P<0.05),随访结果显示,米非司酮及孕三烯酮组症状完全缓解率分别为85.2%和88.2%,两组复发率分别为5.9%和2.9%,两组疗效及复发率比较差异无统计学意义(P>0.05)。患者的不良反应米非司酮显著小于孕三烯酮。结论:米非司酮与孕三烯酮用于盆腔子宫内膜异位症手术后巩固治疗,安全、有效、不良反应轻。
Objective： To observe the clinical efficacy of mifepristone and gestrinone in consolidation therapy after operation of pelvic endometriosis. Methods： 68 cases undergoing conservative surgery and diagnosed as pelvic endometriosis by pathological examination from June 2008 to June 2009 were divided into 2 groups randomly： 34 cases in mifepristone group took mifepristone, 2. 5 mg per day ; 34 cases in gestrinone group took gestrinone, 12. 5 mg each time, twice a week. The treatment started after one week and continued for 6 months, follow - up was carried out regularly. Results： The rates of dysmenorrhea and other painful symptoms in the two groups after treatment were significantly lower than those before treatment （ P 〈 0. 05 ）, follow - up results showed that complete remission rates in mifepristone group and gestrinone group were 85.2% and 88.2%, respectively, the relapse rates in mifepristone group and gestrinone group were 5.9% and 2. 9% , respectively, there was no significant difference （P 〉 0.05 ） . The incidence of adverse reactions in mifepristone group was significan（ly lower than that in gestrinone group. Conclusion： Application of mifepristone and gestrinone in consolidation therapy after operation of pelvic endometriosis is safe and effective, without severe adverse reactions.
出处
《中国妇幼保健》
CAS
北大核心
2010年第6期842-843,共2页
Maternal and Child Health Care of China
